PMID- 16322295
OWN - NLM
STAT- MEDLINE
DCOM- 20060124
LR  - 20141120
IS  - 1078-0432 (Print)
IS  - 1078-0432 (Linking)
VI  - 11
IP  - 23
DP  - 2005 Dec 1
TI  - Expression of HER2 and the coamplified genes GRB7 and MLN64 in human breast 
      cancer: quantitative real-time reverse transcription-PCR as a diagnostic 
      alternative to immunohistochemistry and fluorescence in situ hybridization.
PG  - 8348-57
AB  - PURPOSE: Accurate testing of HER2 is centrally important for breast cancer 
      therapy and prognosis. Immunohistochemistry (IHC) and fluorescence in situ 
      hybridization (FISH) are current standard testing methods. As a potential 
      alternative for assessment of HER2, we explored quantitative real-time reverse 
      transcription-PCR (RT-PCR), a fast and inexpensive method yielding quantitative 
      results insensitive to interobserver variability and amenable to standardized 
      scoring. EXPERIMENTAL DESIGN: We assessed HER2 status at the DNA, mRNA, and 
      protein levels with FISH, quantitative RT-PCR, and IHC in 136 tumor samples from 
      85 breast cancer patients. Expression of GRB7, MLN64, and p21, genes coregulated 
      with HER2, was also quantified with quantitative RT-PCR and correlated with the 
      overall survival (OS) and disease-free survival (DFS) individually and in 
      combination with HER2. RESULTS: Twenty-nine percent and 19% of the patients 
      scored HER2 positive with IHC and quantitative RT-PCR, respectively. In 18 of 19 
      cases, HER2 statuses in tumors and lymph node metastases were identical. HER2 
      status significantly correlated with DFS when determined by IHC (P < 0.01), 
      quantitative RT-PCR (P < 0.003), but not with FISH (P = 0.09). The combination of 
      HER2 with MLN64, but not with GRB7 or p21, enhanced the prognostic power for the 
      DFS (P < 0.00005) and OS (P < 0.0008). CONCLUSIONS: Quantitative RT-PCR seems to 
      be clinically as useful in the assessment of HER2 status as IHC and FISH, 
      yielding comparable correlations of HER2 status with the OS and DFS. Thus, 
      quantitative RT-PCR analysis of HER2 or HER2 plus MLN64 is a promising complement 
      or alternative to current methods for HER2 testing, particularly in laboratories 
      lacking FISH or IHC technology.
FAU - Vinatzer, Ursula
AU  - Vinatzer U
AD  - Department of Obstetrics and Gynecology, Medical University of Vienna, and 
      Boehringer Ingelheim Austria, Vienna, Austria.
FAU - Dampier, Brigitta
AU  - Dampier B
FAU - Streubel, Berthold
AU  - Streubel B
FAU - Pacher, Margit
AU  - Pacher M
FAU - Seewald, Michael J
AU  - Seewald MJ
FAU - Stratowa, Christian
AU  - Stratowa C
FAU - Kaserer, Klaus
AU  - Kaserer K
FAU - Schreiber, Martin
AU  - Schreiber M
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Clin Cancer Res
JT  - Clinical cancer research : an official journal of the American Association for 
      Cancer Research
JID - 9502500
RN  - 0 (CDKN1A protein, human)
RN  - 0 (Carrier Proteins)
RN  - 0 (Cyclin-Dependent Kinase Inhibitor p21)
RN  - 0 (DNA, Neoplasm)
RN  - 0 (GRB7 protein, human)
RN  - 0 (Membrane Proteins)
RN  - 0 (STARD3 protein, human)
RN  - 149058-53-7 (GRB7 Adaptor Protein)
RN  - EC 2.7.10.1 (Receptor, ErbB-2)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Breast Neoplasms/*genetics/metabolism/pathology
MH  - Carcinoma, Ductal, Breast/genetics/metabolism/pathology
MH  - Carcinoma, Lobular/genetics/metabolism/pathology
MH  - Carrier Proteins/*genetics/metabolism
MH  - Cyclin-Dependent Kinase Inhibitor p21/genetics/metabolism
MH  - DNA, Neoplasm/analysis
MH  - Female
MH  - GRB7 Adaptor Protein/*genetics/metabolism
MH  - Gene Amplification
MH  - *Gene Expression Regulation, Neoplastic
MH  - Humans
MH  - Immunoenzyme Techniques
MH  - In Situ Hybridization, Fluorescence
MH  - Lymphatic Metastasis/pathology
MH  - Membrane Proteins/*genetics/metabolism
MH  - Middle Aged
MH  - Neoplasm Staging
MH  - Prognosis
MH  - Receptor, ErbB-2/*genetics/metabolism
MH  - Retrospective Studies
MH  - Reverse Transcriptase Polymerase Chain Reaction
MH  - Survival Rate
EDAT- 2005/12/03 09:00
MHDA- 2006/01/25 09:00
CRDT- 2005/12/03 09:00
PHST- 2005/12/03 09:00 [pubmed]
PHST- 2006/01/25 09:00 [medline]
PHST- 2005/12/03 09:00 [entrez]
AID - 11/23/8348 [pii]
AID - 10.1158/1078-0432.CCR-05-0841 [doi]
PST - ppublish
SO  - Clin Cancer Res. 2005 Dec 1;11(23):8348-57. doi: 10.1158/1078-0432.CCR-05-0841.